(Reuters) - The agreement is the largest drug discovery partnership in the field to date and a further vindication of the emerging area of biotechnology research which involves blocking disease-causing proteins.
Roche will pay Alnylam $331 million upfront in cash and equity investment, including a stake of 1.975 million Alnylam shares at $21.50 each, or just under 5 percent of Alnylam's outstanding common stock, the two firms said on Monday.
Read more at Reuters.com Business News
Roche will pay Alnylam $331 million upfront in cash and equity investment, including a stake of 1.975 million Alnylam shares at $21.50 each, or just under 5 percent of Alnylam's outstanding common stock, the two firms said on Monday.
Read more at Reuters.com Business News
No comments:
Post a Comment